Form 13-F position report

* UNITED THERAPEUTICS CORP DE

Reported by Longaeva Partners L P

UTHR CUSIP 91307C102 Manager CIK 0002054122

First reported at 106,803 shares this quarter.

New
% of reported 13F value 1.2% This manager · Q3 2026
Shares 106,803 Quarter-end amount reported
Reported value $57,875,478 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-09-30 57875478

Quarterly position history

How this manager's reported quarter-end position changed over time.

1 quarter
Quarterly reported position history for * UNITED THERAPEUTICS CORP DE held by Longaeva Partners L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 106,803 +106,803 (0.0%) 1.2% $57,875,478 2026-11-16

Who else reported the position

962 managers reported * UNITED THERAPEUTICS CORP DE for Q3 2026.

Managers reporting * UNITED THERAPEUTICS CORP DE in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 5,575,162 +280,633 0.04% $3,021,124,690 9 qtrs
Avoro Capital Advisors LLC Reduced 2,755,555 -22,222 15.41% $1,493,207,699 24 qtrs
STATE STREET CORPORATION Added 1,952,557 +54,493 0.03% $1,058,071,113 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 1,928,928 +10,672 0.02% $1,045,266,794 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 1,911,530 -7,899 0.05% $1,035,838,992 3 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 1,899,605 +520,580 0.18% $1,029,376,955 24 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 1,675,899 -32,840 1.24% $908,152,909 54 qtrs
AMUNDI Added 988,820 +769,726 0.11% $535,831,670 22 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 974,993 -21,605 0.03% $527,238,922 54 qtrs
CITADEL ADVISORS LLC Added 928,464 +623,772 0.06% $503,125,357 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
106,803
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.